CONSHOHOCKEN, PA — Researchers, clinicians and patient advocates have established the first consensus definitions for key treatment and disease-management terms in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a move intended to improve consistency in patient care, clinical trials, and communication between physicians and patients.
The framework, published June 16 in Neurology, the medical journal of the American Academy of Neurology, addresses longstanding variations in how clinicians define concepts such as treatment response, relapse, and remission in patients with CIDP.
The effort was led by the GBS|CIDP Foundation International through its Leadership Collaborative initiative, which brings together patients, medical experts and researchers to address challenges affecting treatment and research in Guillain-Barré syndrome, CIDP and multifocal motor neuropathy.
According to the foundation, the absence of standardized terminology has historically created inconsistencies in clinical practice and research, with physicians often relying on individual interpretations when evaluating disease progression and treatment outcomes.
“Progress is often slowed when there is a disconnect between how patients describe their symptoms and how clinicians interpret them,” stated Dr. Jeffrey Allen, associate professor of neurology at the University of Minnesota and chair of the foundation’s Global Medical Advisory Board. “By establishing a shared language, we hope to improve communication between patients and healthcare providers, leading to better disease management and improved preparedness for clinical research and trials.”
Allen added that a common set of definitions could help patients and physicians collaborate more effectively throughout the treatment process.
The consensus framework was developed through a multi-step process that began with discussions at an international meeting. The foundation subsequently convened a two-day patient workshop to gather input on how disease-related terms should be understood and applied in clinical settings.
Following the patient engagement phase, a panel of international CIDP experts finalized the definitions using a modified Delphi consensus model, a structured methodology designed to achieve agreement among specialists.
CIDP is a rare autoimmune neurological disorder characterized by progressive weakness and sensory loss in the arms and legs. Symptoms typically develop over six to 10 weeks and occur on both sides of the body. Without treatment, the disease can lead to significant disability, including wheelchair dependence.
The publication, titled “Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy,” is available in Neurology at https://www.neurology.org/doi/10.1212/WNL.0000000000218159.
The foundation expects the standardized definitions to support future clinical research, improve consistency across trials and help establish a shared understanding of treatment outcomes among patients, clinicians and researchers.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.